CADL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -7.75%, SMA50 -10.34%, SMA200 -7.57%). The stock’s 14-day RSI is 41.21 (neutral), while the ATR of 0.35 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.08% below its high and over 21.18% above its low. Average 10-day trading volume of 1.61 million shares is below the 3-month average of 1.79 million, indicating normal recent market interest.

Candel Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.22. This means the shares are trading above this model’s fair value.

Candel Therapeutics, Inc. has 54.90 million shares outstanding. The public float is 45.48 million shares, elevated short interest at 16.73% of float. This equals 7.27 million shares. The short ratio is 12.15 days. Institutional investors hold 50.8% of the float. Insiders own 16.76%. Manning Paul B holds 2.76 million shares, Aguilar-Cordova Estuardo has 919.46 thousand shares and Tak Paul Peter has 225.74 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Candel Therapeutics, Inc. (NASDAQ:CADL) closed at $9.28 USD, gaining $0.48 (5.45%) from the previous close of $8.80. The stock is currently within 5% of its 52-week high $4.35 and $9.57. With a market capitalization of about $509.48 million, Candel Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.58). Key stats such as the average daily volume over the past year has been around 1.76 million shares, trading with heavier-than-usual volume. Headquartered in Needham, MA, Candel Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul-Peter Tak, the company employs approximately 38 people and listed since July 27, 2021. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

Candel Therapeutics, Inc. generated EPS of -$0.56 over the past year. Five-year average earnings growth is -43.86%. Wall Street analysts project EPS growth of 34.45% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.24. Next year's EPS is expected at $2.69. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $7.00. The high target offers 195.45% upside. The low target suggests -20.45% downside. The mean target is $18.57. This offers 111.02% upside. Candel Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -52.68%. The prior quarter beat by 125.0%. Over the last six quarters, Apple has recorded several small beats. These include 73.91% in March 13, 2025.

Candel Therapeutics, Inc. trades at a P/E ratio of -10.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.01 trading at moderately above to book value. The P/FCF stands at -9.94, also above market averages.

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are flat 4.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Candel Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.63, suggesting 88.98% upside. Our AI forecast model points to short-term strength (10.23% over two weeks), a medium-term rise (87.5% over three months), and a longer-term gain (110.57% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Candel Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.23%, with price expected at $9.70 by June 17, 2026, within a range of $8.81 to $10.63 3-Month Outlook: Projected rise of 87.5%, reaching $16.50 by September 01, 2026, with a range of $15.55 to $17.48. 1-Year Outlook: Projected gain of 110.57%, with price at $18.53 by June 03, 2027, within a range of $4.52 to $27.94.